恒瑞医药(01276.HK)自主研发的 1 类创新药海曲泊帕乙醇胺片获批新增两项适应症

智通财经
Sep 10
【恒瑞医药(01276.HK)自主研发的 1 类创新药海曲泊帕乙醇胺片获批新增两项适应症】智通财经APP讯,恒瑞医药(01276.HK)公布,近日,公司收到国家药品监督管理局的通知,批准公司自主研发的 1 类创新药海曲泊帕乙醇胺片新增两项适应症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10